Arvee Laborat.

Who are the top shareholders of the Arvee Laborat.?

The top shareholders of Arvee Laborat are Shalin Sudhakarbhai Patel, holding 36.68%, and Gitaben Dinehsbhai Patel, with 9.98%. Individual investors collectively own 26.33%, with no mutual funds or foreign institutional investors involved.

The top shareholders of Arvee Laborat include Shalin Sudhakarbhai Patel, who is the promoter with the highest holding at 36.68%. The highest public shareholder is Gitaben Dinehsbhai Patel, holding 9.98%. Additionally, individual investors collectively hold 26.33% of the company's shares. There are no mutual funds or foreign institutional investors currently holding shares in the company.

how big is Arvee Laborat.?

As of Jun 06, Arvee Laboratories (India) Ltd has a market capitalization of 196.00 Cr and reported net sales of 38.49 Cr and net profit of 2.14 Cr over the latest four quarters. Shareholder's funds are 29.11 Cr, with total assets of 38.20 Cr as of Mar'24.

Market Cap: As of Jun 06, Arvee Laboratories (India) Ltd has a market capitalization of 196.00 Cr, classified as a Micro Cap.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters, which includes the periods of Mar'25, Dec'24, Sep'24, and Jun'24, is 38.49 Cr. The sum of Net Profit for the same quarters is 2.14 Cr. This data is presented on a Standalone basis.<BR><BR>Balance Sheet Snapshot: This is Standalone data for the latest annual period ending in Mar'24. Shareholder's Funds are reported at 29.11 Cr, while Total Assets amount to 38.20 Cr.

What does Arvee Laborat. do?

Arvee Laboratories (India) Ltd manufactures specialized chemicals and is classified as a Micro Cap company. As of March 2025, it reported net sales of 6 Cr and a net profit of 0 Cr, with a market cap of Rs 196 Cr.

Overview: <BR>Arvee Laboratories (India) Ltd is engaged in the manufacturing of specialized chemicals and operates within the Chemicals & Petrochemicals industry, classified as a Micro Cap company.<BR><BR>History: <BR>The company was incorporated in 2012 as a Private Limited Company and later converted to a Public Limited Company in 2017. The most recent quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>- Net Sales: 6 Cr (Quarterly Results - Mar 2025) <BR>- Net Profit: 0 Cr (Quarterly Results - Mar 2025) <BR>- Market Cap: Rs 196 Cr (Micro Cap) <BR><BR>Key Metrics: <BR>- P/E: 92.00 <BR>- Industry P/E: 47 <BR>- Dividend Yield: 0.00% <BR>- Debt Equity: -0.16 <BR>- Return on Equity: 6.85% <BR>- Price to Book: 6.27 <BR><BR>Contact Details: <BR>Address: 49/3 B Shyamal Row House, 100 Feet Road Satelitte Ahmedabad Gujarat : 380015 <BR>Tel: 91-79-26749036/37/38 <BR>Email: shalin.patel@arveelabs.com <BR>Website: http://www.arveelabs.com

When is the next results date for Arvee Laborat.?

No Upcoming Board Meetings

What is the bonus history of the Arvee Laborat.?

Arvee Laboratories (India) Ltd issued a 1:1 bonus on October 13, 2020, with a record date of October 14, 2020, allowing shareholders to receive one additional share for each share held.

Arvee Laboratories (India) Ltd has a bonus history that includes a 1:1 bonus issue announced with an ex-date of October 13, 2020. The record date for this bonus was October 14, 2020. This means that shareholders on record as of that date received an additional share for each share they held.

Has Arvee Laborat. declared dividend?

No Dividend History Available

Who are the peers of the Arvee Laborat.?

Peers of Arvee Laborat. include Indian Emuls, Hindcon Chemical, Shri Ahimsa, and others, with similar management risks and growth ratings. All peers, including Arvee Laborat., have a 1-year and six-month return of 0.00%.

Peers: The peers of Arvee Laborat. are Indian Emuls, Hindcon Chemical, Shri Ahimsa, Indian Phosphate, Hi-Green Carbon, Vital Chemtech, Jocil, Paragon Fine, Par Drugs & Che., Mahickra Chem.<BR><BR>Quality Snapshot: Excellent management risk is observed at Indian Emuls, Shri Ahimsa, and Paragon Fine, while Average management risk is found at Hindcon Chemical, Hi-Green Carbon, Vital Chemtech, Jocil, Par Drugs & Che., Mahickra Chem, and Arvee Laborat. Growth is rated as Excellent for Indian Emuls, while Below Average growth is noted for Hindcon Chemical, Shri Ahimsa, Indian Phosphate, Vital Chemtech, Jocil, Paragon Fine, Par Drugs & Che., Mahickra Chem, and Arvee Laborat. Capital Structure is Excellent at Hindcon Chemical, Shri Ahimsa, Jocil, and Par Drugs & Che., while Average is seen at Indian Emuls and Vital Chemtech, and Good at Indian Phosphate, Hi-Green Carbon, Paragon Fine, and Arvee Laborat.<BR><BR>Return Snapshot: All peers, including Arvee Laborat., have a 1-year return of 0.00%, indicating no variation among them. Therefore, there is no peer with a higher or lower return compared to Arvee Laborat. Additionally, all peers have a six-month return of 0.00%, indicating no negative returns.

What is the technical trend for Arvee Laborat.?

As of June 5, 2025, Arvee Laborat's technical trend is neutral with a slight bearish inclination in the short term, driven by mixed MACD signals and mildly bearish daily moving averages.

As of 5 June 2025, the technical trend for Arvee Laborat has changed from mildly bullish to sideways. The weekly MACD remains bullish, while the monthly MACD is mildly bearish, indicating mixed signals. The Bollinger Bands show a mildly bullish stance on the weekly chart but are sideways on the monthly chart. Moving averages on the daily timeframe are mildly bearish, suggesting short-term weakness. The KST and Dow Theory both indicate a mildly bullish outlook on the weekly and monthly charts. Overall, the current technical stance is neutral with a slight bearish inclination in the short term, driven primarily by the daily moving averages and the mixed signals from the MACD.

Who are in the management team of Arvee Laborat.?

As of March 2020, the management team of Arvee Laborat includes Shalin Sudhakarbhai Patel (Chairman & Managing Director), Shalin Bharat Chokshi (Whole-time Director), and seven Independent Directors: Chandrakala Ashok Bhatt, Vishal Nitin Mehta, Amishkumar Maheshkumar Shah, Paragbhai Manubhai Shah, Neetu Jalan, and Sachin Kanwarlal Kansal. Each member contributes to the company's governance and strategic direction.

As of March 2020, the management team of Arvee Laborat consists of the following individuals:<BR><BR>1. Shalin Sudhakarbhai Patel - Chairman & Managing Director<BR>2. Shalin Bharat Chokshi - Whole-time Director<BR>3. Chandrakala Ashok Bhatt - Independent Director<BR>4. Vishal Nitin Mehta - Independent Director<BR>5. Amishkumar Maheshkumar Shah - Independent Director<BR>6. Paragbhai Manubhai Shah - Independent Director<BR>7. Neetu Jalan - Independent Director<BR>8. Sachin Kanwarlal Kansal - Independent Director<BR><BR>Each member plays a significant role in the governance and strategic direction of the company.

How has been the historical performance of Arvee Laborat.?

Arvee Laborat has experienced significant fluctuations in financial performance, with net sales and profits declining from March 2023 to March 2025, despite slight improvements in cash flow. Key metrics such as operating profit and earnings per share also decreased during this period.

Answer:<BR>The historical performance of Arvee Laborat shows significant fluctuations in key financial metrics over the years.<BR><BR>Breakdown:<BR>Arvee Laborat's net sales have varied considerably, peaking at 62.48 Cr in March 2023 before declining to 38.49 Cr in March 2025. The total operating income followed a similar trend, reaching its highest at 62.48 Cr in March 2023 and dropping to 38.49 Cr in March 2025. The raw material cost has also seen an increase, from 18.87 Cr in March 2025 compared to 16.98 Cr in March 2024, while total expenditure excluding depreciation decreased from 54.07 Cr in March 2023 to 34.87 Cr in March 2025. Operating profit (PBDIT) has fluctuated, with a high of 8.63 Cr in March 2023 and a decrease to 4.28 Cr in March 2025. Profit before tax showed a decline from 6.17 Cr in March 2023 to 2.87 Cr in March 2025, while profit after tax also decreased from 4.12 Cr in March 2023 to 2.15 Cr in March 2025. The earnings per share (EPS) reflected this trend, dropping from 3.74 in March 2023 to 1.95 in March 2025. On the balance sheet, total assets decreased from 38.69 Cr in March 2023 to 38.20 Cr in March 2024, while total liabilities remained relatively stable. Cash flow from operating activities improved slightly from 2.00 Cr in March 2023 to 3.00 Cr in March 2024, with a net cash inflow of 1.00 Cr in March 2024. Overall, the financial performance of Arvee Laborat indicates a challenging period with declining revenues and profits, despite some improvements in cash flow.

Is Arvee Laborat. overvalued or undervalued?

As of November 17, 2025, Arvee Laboratories is considered overvalued and risky, with a PE ratio of 461.66 and an EV to EBITDA of 171.93, significantly higher than its peers, despite a strong historical stock performance.

As of 17 November 2025, the valuation grade for Arvee Laboratories has moved from very expensive to risky, indicating a significant shift in its perceived value. The company is currently considered overvalued. Key ratios highlight this concern, with a PE ratio of 461.66, an EV to EBITDA of 171.93, and a ROE of just 1.27%. <BR><BR>In comparison to its peers, Arvee's valuation metrics are starkly higher; for instance, Solar Industries has a PE of 95.31 and Gujarat Fluoroch at 57.85, both categorized as very expensive. The high PE ratio and negative EV to EBIT of -178.80 further underscore the risk associated with Arvee's current valuation. Despite a strong performance over the last five years, where the stock returned 303.78% compared to the Sensex's 102.06%, the current valuation suggests that investors should approach with caution.

Are Arvee Laboratories (India) Ltd latest results good or bad?

The latest results for Arvee Laboratories (India) Ltd are concerning, showing a net profit decline of 94.12% quarter-on-quarter and 98.98% year-on-year, with revenue down 53.88% from the previous quarter. These figures indicate serious operational challenges and suggest a fundamental breakdown in the business model, characterizing the results as bad.

The latest results for Arvee Laboratories (India) Ltd are quite concerning. In Q2 FY26, the company reported a net profit of just ₹0.01 crore, which reflects a staggering decline of 94.12% quarter-on-quarter and 98.98% year-on-year. Revenue also took a significant hit, falling to ₹3.45 crores, down 53.88% from the previous quarter and down 72.47% compared to the same quarter last year.<BR><BR>Operating margins have collapsed from 12.05% a year ago to only 3.48% in the latest quarter, indicating severe operational challenges. The profit after tax margin has similarly deteriorated to 0.29%, down from 7.82% in the same period last year. <BR><BR>Overall, these results indicate that the company is facing serious difficulties, with a dramatic decline in both revenue and profitability. The operational metrics suggest a fundamental breakdown in the business model rather than a temporary setback. Given these figures, the latest results can be characterized as bad, raising significant concerns about the company's future viability.

Should I buy, sell or hold Arvee Laboratories (India) Ltd?

Why is Arvee Laboratories (India) Ltd falling/rising?

As of 26-Mar, Arvee Laboratories (India) Ltd's stock price has risen to 141.24, reflecting a short-term increase despite a significant decline in performance over the past week and month. The stock's fundamentals indicate ongoing challenges, suggesting that the recent price rise may not be sustainable.

As of 26-Mar, Arvee Laboratories (India) Ltd is experiencing a rise in its stock price, currently at 141.24, which reflects an increase of 3.24 or 2.35%. This uptick in price comes despite the stock's recent performance, which shows a decline of 5.84% over the past week and 8.29% over the past month. Year-to-date, the stock has fallen significantly by 33.79, compared to a 10.80% decline in the benchmark Sensex.<BR><BR>Today's performance indicates that the stock has outperformed its sector by 0.65%, which may contribute to the positive movement in price. However, it is important to note that the stock is trading below its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, suggesting a general trend of weakness.<BR><BR>Additionally, the stock is close to its 52-week low, being only 4.67% away from Rs 134.65. The company's fundamentals indicate weak long-term growth, with a -20.49% CAGR in operating profits over the last five years and a low return on equity of 6.6. The company's net sales have also seen a significant decline of 38.29% over the latest six months.<BR><BR>In summary, while there is a short-term rise in the stock price, the underlying fundamentals and recent performance trends suggest ongoing challenges for Arvee Laboratories (India) Ltd, indicating that this rise may not be sustainable in the long term.

Why is Arvee Laboratories (India) Ltd falling/rising?

As of 27-Mar, Arvee Laboratories (India) Ltd's stock price has declined to Rs. 134.20, reflecting a drop of -4.98%. This decline is due to weak financial fundamentals, poor performance relative to the benchmark Sensex, and negative market sentiment, leading to a new 52-week low.

As of 27-Mar, Arvee Laboratories (India) Ltd is experiencing a decline in its stock price, currently at Rs. 134.20, which reflects a change of -7.04 (-4.98%). This drop can be attributed to several factors highlighted in the source data. <BR><BR>Firstly, the stock has hit a new 52-week low today, indicating a significant decrease in investor confidence. Over the past week, the stock has underperformed the benchmark Sensex, showing a decline of -8.18% compared to the Sensex's -1.28%. Additionally, the stock's performance over the last month has also been poor, with a decrease of -13.42%, while the Sensex fell by only -9.37%.<BR><BR>The company's financial fundamentals are weak, as evidenced by a -20.49% compound annual growth rate (CAGR) in operating profits over the last five years. The latest net sales figures show a substantial decline of -38.29%, further indicating operational challenges. The return on equity (ROE) is low at 6.6%, and the stock is trading at a premium compared to its peers, with a price-to-book value of 4.7, suggesting an expensive valuation relative to its profitability.<BR><BR>Moreover, the stock is trading below its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which typically signals a bearish trend. The liquidity of the stock is also noted to be low, based on the average traded value.<BR><BR>In summary, the combination of poor financial performance, weak fundamentals, and negative market sentiment has contributed to the decline in Arvee Laboratories' stock price.

Why is Arvee Laboratories (India) Ltd falling/rising?

As of 28-Mar, Arvee Laboratories (India) Ltd's stock price has declined to Rs. 134.20, down 4.98%, due to weak fundamentals, significant underperformance against the Sensex, and negative technical indicators. The stock has hit a 52-week low, reflecting low investor confidence and high valuation relative to its profitability.

As of 28-Mar, Arvee Laboratories (India) Ltd is experiencing a decline in its stock price, currently at Rs. 134.20, which reflects a decrease of Rs. 7.04 or 4.98%. This drop can be attributed to several factors highlighted in the provided data. <BR><BR>Firstly, the stock has underperformed significantly compared to the benchmark Sensex, with a 1-week decline of 8.18% versus the Sensex's 1.28%. Over the past month, the stock has fallen by 13.42%, while the Sensex has decreased by only 9.37%. Year-to-date, Arvee Laboratories has seen a staggering decline of 37.09%, compared to the Sensex's 12.67%. <BR><BR>Additionally, the stock has hit a new 52-week low today, indicating a lack of investor confidence. It is also trading below its moving averages across various time frames (5-day, 20-day, 50-day, 100-day, and 200-day), which typically signals a bearish trend. The performance today has underperformed its sector by 2.72%, further contributing to the negative sentiment surrounding the stock.<BR><BR>The company's fundamentals are weak, with a -20.49% compound annual growth rate (CAGR) in operating profits over the last five years, and a return on equity (ROE) of only 6.6%, suggesting low profitability. The net sales for the latest six months have decreased by 38.29%, and the return on capital employed (ROCE) is at its lowest point of 2.09%. Moreover, the stock is trading at a premium compared to its peers, with a price-to-book value of 4.7, which is considered expensive given its low profitability metrics.<BR><BR>Overall, the combination of poor financial performance, significant underperformance relative to the market, and negative technical indicators has led to the decline in Arvee Laboratories' stock price.

Why is Arvee Laboratories (India) Ltd falling/rising?

As of 29-Mar, Arvee Laboratories (India) Ltd's stock price has declined to Rs. 134.20, reflecting a -4.98% change, primarily due to significant underperformance against the Sensex and weak financial fundamentals, including a low return on equity and a new 52-week low. This indicates a lack of investor confidence and a bearish trend in the stock.

As of 29-Mar, Arvee Laboratories (India) Ltd is experiencing a decline in its stock price, currently at Rs. 134.20, which reflects a change of -7.04 (-4.98%). This drop can be attributed to several factors highlighted in the provided data. <BR><BR>Firstly, the stock has underperformed significantly compared to the benchmark Sensex, with a 1-week decline of -8.18% against the Sensex's -1.28%, and a 1-month decrease of -13.42% compared to the Sensex's -9.37%. Year-to-date, the stock has fallen by -37.09%, while the Sensex has only decreased by -12.67%. Such underperformance indicates a lack of investor confidence in the company relative to the broader market.<BR><BR>Additionally, the stock has hit a new 52-week low today, which often signals negative sentiment among investors. The performance today has also underperformed the sector by -2.72%. The stock is trading below its moving averages across various time frames (5-day, 20-day, 50-day, 100-day, and 200-day), suggesting a bearish trend.<BR><BR>Financially, the company has shown weak long-term fundamental strength, with a -20.49% compound annual growth rate (CAGR) in operating profits over the last five years. The net sales for the latest six months have decreased by -38.29%, and the return on capital employed (ROCE) is at its lowest point of 2.09%. Furthermore, the return on equity (ROE) is low at 6.6%, indicating low profitability per unit of shareholders' funds. The stock is also trading at a premium compared to its peers, with a price-to-book value of 4.7, which may deter potential investors.<BR><BR>Overall, the combination of poor financial performance, significant underperformance relative to the market, and negative investor sentiment has contributed to the decline in Arvee Laboratories (India) Ltd's stock price.

Which are the latest news on Arvee Laborat.?

Which are the latest news on Arvee Laborat.?

Which are the latest news on Arvee Laborat.?